Twelve months of edoxaban is superior to three months for the reduction of thrombotic events in patients with cancer and distal deep vein thrombosis (DVT), according to late breaking research presented in a Hot Line session today at ESC Congress 2023.
FDA advisory committee says risks of Novo Nordisk’s once-weekly insulin outweigh benefits in type 1 diabetes patients
An FDA advisory committee on Friday voted not to recommend Novo Nordisk’s once-weekly insulin injection in type 1 diabetes patients. Novo has pitched its candidate
May 25, 2024